BOSTON--(BUSINESS WIRE)--Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that it will discontinue development of its TNG348 program.

波士顿--（商业新闻短讯）--Tango Therapeutics，Inc.（纳斯达克：TNGX），一家致力于发现和提供下一代精准癌症药物的临床阶段生物技术公司，今天宣布将停止其TNG348计划的开发。

“Patient safety is always our first priority and based on emerging data from the TNG348 dose escalation study, we have made the decision to discontinue further development of this molecule due to liver toxicity experienced by patients in the trial. While disappointing, we believe this is the right decision given the data at hand,” said Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics.

Tango Therapeutics总裁兼首席执行官芭芭拉·韦伯（BarbaraWeber）医学博士说：“患者安全始终是我们的首要任务，根据TNG348剂量递增研究的新数据，我们决定停止进一步开发这种分子，因为患者在试验中经历了肝毒性。尽管令人失望，但鉴于手头的数据，我们认为这是正确的决定。”。

“We will focus resources and capital on our existing portfolio, particularly our PRMT5 program. We remain committed to and confident in our ability to deliver a comprehensive clinical update on TNG908 and TNG462 in the second half of this year.”.

“我们将把资源和资本集中在现有的投资组合上，特别是我们的PRMT5计划。我们仍然致力于并相信我们有能力在今年下半年对TNG908和TNG462进行全面的临床更新。”。

TNG348 was being studied in a phase 1/2 clinical trial evaluating safety, pharmacokinetics, pharmacodynamics and efficacy as a single agent and in combination with olaparib, a PARP inhibitor, in patients with BRCA1/2-mutant and other HRD+ (homologous recombination deficient) cancers. Grade 3/4 liver function abnormalities were observed in patients remaining on study longer than eight weeks, leading to the decision to terminate the program.

TNG348正在一项1/2期临床试验中进行研究，该试验评估了BRCA1/2突变型和其他HRD+（同源重组缺陷型）癌症患者作为单一药物以及与PARP抑制剂olaparib联合使用的安全性，药代动力学，药效学和有效性。在研究时间超过八周的患者中观察到3/4级肝功能异常，导致决定终止该计划。

No patient had yet received a combination of TNG348 and olaparib..

尚未有患者接受TNG348和奥拉帕尼的联合治疗。。

About Tango Therapeutics

关于探戈疗法

Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.

Tango Therapeutics是一家临床阶段的生物技术公司，致力于发现新的药物靶标并提供下一代用于治疗癌症的精准药物。Tango采用以患者为起点和终点的方法，利用合成致死性的遗传原理来发现和开发针对癌症关键靶点的疗法。

This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. For more information, please visit www.tangotx.com..

这包括将精确肿瘤学靶标的范围扩展到新的领域，例如肿瘤抑制基因的丢失及其对癌细胞逃避免疫细胞杀伤能力的贡献。有关更多信息，请访问www.tangotx.com。。

Forward-Looking Statements

前瞻性声明

Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events, Tango’s future operating performance and goals, the anticipated benefits of therapies and combination therapies (that include a Tango pipeline product), as well as the expectations, beliefs and development objectives for Tango’s product pipeline and clinical trials.

本新闻稿中的某些声明可能被视为前瞻性声明。前瞻性陈述通常涉及未来事件，Tango未来的经营业绩和目标，治疗和联合治疗（包括Tango管道产品）的预期益处，以及Tango产品管道和临床试验的期望，信念和发展目标。

In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “goal”, “estimate”, “anticipate”, “believe”, “predict”, “designed,” “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. For example, implicit or explicit statements include, but are not limited to, the following: statements regarding Tango’s plans to progress its TNG908 and TNG462 programs, including timing and expectations to provide an update related thereto; and Tango’s expectations regarding its use of capital and the extension of its cash runway.

在某些情况下，您可以通过诸如“可能”、“应该”、“期望”、“打算”、“意志”、“目标”、“估计”、“预期”、“相信”、“预测”、“设计”、“潜在”或“继续”等术语来识别前瞻性陈述，或者这些术语的否定或其变体或类似术语。例如，隐含或明确的声明包括但不限于以下内容：关于Tango计划推进其TNG908和TNG462计划的声明，包括提供相关更新的时间和期望；以及Tango对其资金使用和现金跑道延长的期望。

Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Tango and its management, are inherently uncertain.

此类前瞻性声明受到风险、不确定性和其他因素的影响，这些因素可能导致实际结果与此类前瞻性声明明示或暗示的结果存在重大差异。这些前瞻性陈述基于估计和假设，虽然Tango及其管理层认为这些估计和假设是合理的，但本质上是不确定的。

New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: benefits of product candidates seen in preclinical tests and analyses may not be evident when tested in later preclinical studies or in c.

新的风险和不确定性可能不时出现，不可能预测所有风险和不确定性。可能导致实际结果与当前预期产生重大差异的因素包括但不限于：在以后的临床前研究或c中进行测试时，在临床前测试和分析中看到的候选产品的益处可能不明显。